Your browser doesn't support javascript.
loading
Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody.
Funakoshi, Yohei; Yakushijin, Kimikazu; Ohji, Goh; Hojo, Wataru; Sakai, Hironori; Watanabe, Marika; Saeki, Miki; Hirakawa, Yuri; Sakai, Rina; Matsumoto, Sakuya; Mizutani, Yu; Kitao, Akihito; Miyata, Yoshiharu; Saito, Yasuyuki; Kawamoto, Shinichiro; Yamamoto, Katsuya; Ito, Mitsuhiro; Nishimura, Meiko; Imamura, Yoshinori; Kiyota, Naomi; Matsuoka, Hiroshi; Mori, Yasuko; Minami, Hironobu.
Afiliação
  • Funakoshi Y; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan. yohei@med.kobe-u.ac.jp.
  • Yakushijin K; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
  • Ohji G; Division of Infection Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
  • Hojo W; R&D, Cellspect Co., Ltd, Morioka, Iwate, Japan.
  • Sakai H; R&D, Cellspect Co., Ltd, Morioka, Iwate, Japan.
  • Watanabe M; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
  • Saeki M; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
  • Hirakawa Y; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
  • Sakai R; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
  • Matsumoto S; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
  • Mizutani Y; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
  • Kitao A; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
  • Miyata Y; BioResource Center, Kobe University Hospital, Kobe, Japan.
  • Saito Y; Division of Molecular and Cellular Signaling, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Kawamoto S; Department of Transfusion Medicine and Cell Therapy, Kobe University Hospital, Kobe, Japan.
  • Yamamoto K; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
  • Ito M; Division of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan.
  • Nishimura M; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
  • Imamura Y; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
  • Kiyota N; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
  • Matsuoka H; Cancer Center, Kobe University Hospital, Kobe, Japan.
  • Mori Y; BioResource Center, Kobe University Hospital, Kobe, Japan.
  • Minami H; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.
Int J Hematol ; 115(1): 7-10, 2022 Jan.
Article em En | MEDLINE | ID: mdl-34981433
ABSTRACT
We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B / Anticorpos Monoclonais Humanizados / COVID-19 / Vacina BNT162 Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B / Anticorpos Monoclonais Humanizados / COVID-19 / Vacina BNT162 Idioma: En Ano de publicação: 2022 Tipo de documento: Article